Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

RAREFIND International Training for Doctoral Research on Advanced Gene and Cell Therapies

Coordinator
Fondazione Telethon Ets, Italy
Runs
1 October 2025 to 30 September 2030
Status
Running
EU funding
€2.6m
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101217387

What the project is doing

In the project's own words, from its summary on CORDIS.

The RAREFIND project is an innovative doctoral training program designed to meet the growing need for specialized education in advanced gene and cell therapies. Coordinated by Fondazione Telethon (FTELE) with the School of Advanced Studies (IUSS) as implementing partner, RAREFIND offers a dynamic interdisciplinary and intersectoral training environment. The program encourages international mobility and promotes excellence in research across FTELE’s leading institutes, TIGEM and SR-TIGET, both recognized for their pioneering contributions to genetic research and therapy development.

RAREFIND aims to train 22 doctoral candidates (DCs) through cutting-edge research projects on gene therapy, gene editing, and related fields. Participants, selected through a rigorous and competitive process, will receive comprehensive education combining scientific expertise with transferable skills. They will gain hands-on experience in leading laboratories, collaborate closely with non-academic entities, and benefit from secondments and specialized training.

This approach ensures exposure to a broad range of perspectives, preparing DCs to advance the development of personalized therapies for rare genetic diseases. A key pillar of the program is its emphasis on career development. RAREFIND offers tailored mentorship, targeted professional skills training, and opportunities to engage with leaders from academia, industry, and regulatory bodies. This holistic approach ensures that graduates are equipped not only for academic research careers but also for leadership roles in biotechnology, pharmaceutical companies, and other sectors in gene and cell therapies.

By integrating translational research with real-world applications, RAREFIND accelerates the transformation of scientific discoveries into therapeutic solutions, strengthening Europe’s biomedical landscape.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Telethon EtsRomaItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI